Chinese biotech Leads Biolabs soared nearly 100% on its first trading day following a HK$1.3 billion ($189 million) initial public offering on the Hong Kong Stock Exchange. The company specializes in antibodies targeting cancer and autoimmune diseases, with a robust pipeline including monoclonal and bispecific antibodies and antibody-drug conjugates. Significant proceeds will support clinical trials, manufacturing upgrades, and general operations as the firm pursues global expansion leveraging its LeadBody antibody platform.